At PureTech, we are developing new categories of therapeutics by leveraging the science of the Brain-Immune-Gut (BIG) axis

 

Our Publications

PureTech is discovering and developing highly differentiated medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis.

The goal at PureTech is to identify, invent, develop, and commercialize innovative new categories of therapeutics that are derived from an advanced understanding of the BIG axis to address significant unmet medical needs.

CASE STUDIES

DISCOVERY REINVENTED

Selective Muscarinic (M1/M4) Receptor Agonists (Karuna)

Open Case Study

The Challenge

Psychosis and severe cognitive impairments are debilitating features of schizophrenia, Alzheimer’s disease and other mental illnesses that affect tens of millions of people

Prognosis for these patients is poor, with no existing medicines that sufficiently and safely treat psychosis and cognition

Existing Approaches

Antipsychotics are the mainstay therapy but  are based on decades old dopamine/ serotonin mechanisms while  pro-cognitive agents offer limited benefits to patients

Existing antipsychotics have serious side effects (e.g., movement disorders, diabetes, weight gain, and cardiovascular related mortality in the elderly)

The Big Idea

A class of medicines (M1/M4 agonists) that showed enormous potential in clinical studies was never developed due to tolerability issues.

We asked “What if you you could selectively target M1/M4 receptors in the central nervous system without affecting the peripheral tissues where most side effects occur?”

The Result

Our KarXT program selectively targets M1/M4 receptors in the brain while blocking their activation in peripheral tissues, thereby unlocking what could be one of the most promising new mechanisms for treating people with schizophrenia  and Alzheimer’s disease

Selective mTORC1 Inhibitors (resTORbio)

Open Case Study

The Challenge

Many of the afflictions of a rapidly aging population – from declines in cognition, to immunosenescence and cancer – remain poorly addressed. One such indication is respiratory tract infection, or RTI, a leading cause of mortality in elderly people

Existing Approaches

Limited therapeutic options exist today to prevent and treat viral respiratory tract infections.

Some vaccines protect against specific viruses; however there is no available treatment for most RTIs, a leading cause of mortality in high risk, elderly populations.

The Big Idea

Can we develop an anti-viral that works by boosting the immune system?

The Result

A new approach in targeting the mTOR pathway by selectively targeting TORC1, linked to increased lifespan and other beneficial effects. We are focusing initially on the reduction of RTIs in elderly individuals at increased risk of RTI related morbidity and mortality. Our selective mTORC1 inhibition program has potential in other aging related indications including cognition, cardiovascular and cancer.

Microbiome-Derived Immune Modulators (Vedanta)

Open Case Study

The Challenge

Immune and infectious diseases can arise when the symbiotic relationship we have with our gut microbiota is disrupted

Existing Approaches

Autoimmune diseases: involve immunosuppression; patients susceptible to opportunistic infections, cancer

Infectious diseases: involve antibiotics; can trigger resistance and lead to reinfection

The Big Idea

What if we could treat immune and infectious disease by mimicking the ways in which the gut microbiota maintains a healthy immune system in humans?

The Result

A novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system to treat infectious disease, autoimmune disorders and cancer

Gamma Delta T-Cells (Internal Pipeline)

Open Case Study

The Challenge

Pancreatic cancer is the 3rd leading cause of cancer death

Globally, 500,000 people are diagnosed each year

>90% are diagnosed at advanced/metastatic stage

Five year survival is <7%

Existing Approaches

Mainstay therapy is chemotherapy, with recently approved regimens offering minimal survival advantage of <2 months on average

No approved targeted approaches exist and checkpoint inhibitors have yet to demonstrate efficacy

The Big Idea

Can we target the immunosuppressive cells that solid, malignant tumors establish to ward off the body’s natural defenses?

The Result

Developing first-in-class monoclonal antibodies targeting immunosuppressive γδ T cells and related mechanisms in pancreatic cancer and other solid tumors

Collaborating with Industry Leaders Across Our Affiliate and Internal R&D Pipelines

 

 

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche